Open Access

Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation

  • Authors:
    • Xiaoming Lin
    • Guangfei Wang
    • Ping Liu
    • Lei Han
    • Tong Wang
    • Kaili Chen
    • Yonglin Gao
  • View Affiliations

  • Published online on: April 16, 2021     https://doi.org/10.3892/etm.2021.10070
  • Article Number: 638
  • Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the effects of gallic acid (GA) on the proliferation and apoptosis of colon cancer cells and to further clarify the mechanism of GA function associated with SRC and EGFR phosphorylation. HCT116 and HT29 cells were treated with different concentrations of GA for 24 h. Cell proliferation and apoptosis were analyzed using plate clone formation and flow cytometry assays, respectively. In addition, the expression of apoptosis‑related proteins was examined by western blotting. Furthermore, the level of STAT3, AKT, SRC and EGFR phosphorylation was analyzed by western blotting and immunofluorescence. Subsequently, the SRC inhibitor PP2 and the EGFR inhibitor gefitinib were used to analyze the GA‑associated mechanisms. In addition, a xenograft tumor model was established to confirm the effects of GA in vivo. The results indicated that GA inhibited cell proliferation and promoted cell apoptosis by upregulating the ratio of cleaved caspase‑3/pro‑caspase‑3 and cleaved caspase‑9/pro‑caspase‑9. Concurrently, GA decreased the level of phosphorylated (p)‑SRC, p‑EGFR, p‑AKT and p‑STAT3. Following treatment with PP2 and gefitinib in both cancer cell lines and animal model, GA was demonstrated to inhibit EGFR and SRC phosphorylation to downregulate STAT3 and AKT phosphorylation. In vivo, GA prevented tumor growth, promoted tumor apoptosis and decreased the level of p‑SRC, p‑EGFR, p‑STAT3 and p‑AKT. In conclusion, GA was indicated to suppress colon cancer proliferation by inhibiting SRC and EGFR phosphorylation.
View Figures
View References

Related Articles

Journal Cover

June-2021
Volume 21 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lin X, Wang G, Liu P, Han L, Wang T, Chen K and Gao Y: Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation. Exp Ther Med 21: 638, 2021
APA
Lin, X., Wang, G., Liu, P., Han, L., Wang, T., Chen, K., & Gao, Y. (2021). Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation. Experimental and Therapeutic Medicine, 21, 638. https://doi.org/10.3892/etm.2021.10070
MLA
Lin, X., Wang, G., Liu, P., Han, L., Wang, T., Chen, K., Gao, Y."Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation". Experimental and Therapeutic Medicine 21.6 (2021): 638.
Chicago
Lin, X., Wang, G., Liu, P., Han, L., Wang, T., Chen, K., Gao, Y."Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation". Experimental and Therapeutic Medicine 21, no. 6 (2021): 638. https://doi.org/10.3892/etm.2021.10070